IL233965B - History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens - Google Patents

History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens

Info

Publication number
IL233965B
IL233965B IL233965A IL23396514A IL233965B IL 233965 B IL233965 B IL 233965B IL 233965 A IL233965 A IL 233965A IL 23396514 A IL23396514 A IL 23396514A IL 233965 B IL233965 B IL 233965B
Authority
IL
Israel
Prior art keywords
derivatives
epoxymetheno
azacyclododecine
tetradehydro
anthra
Prior art date
Application number
IL233965A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47722570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL233965(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL233965B publication Critical patent/IL233965B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL233965A 2012-02-13 2014-08-06 History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens IL233965B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261598143P 2012-02-13 2012-02-13
US201261653785P 2012-05-31 2012-05-31
PCT/US2013/025247 WO2013122823A1 (en) 2012-02-13 2013-02-08 Enediyne compounds, conjugates thereof, and uses and methods therefor

Publications (1)

Publication Number Publication Date
IL233965B true IL233965B (en) 2018-01-31

Family

ID=47722570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233965A IL233965B (en) 2012-02-13 2014-08-06 History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens

Country Status (31)

Country Link
US (2) US8709431B2 (OSRAM)
EP (1) EP2814829B1 (OSRAM)
JP (1) JP6113194B2 (OSRAM)
KR (1) KR101660146B1 (OSRAM)
CN (1) CN104220441B (OSRAM)
AR (1) AR089972A1 (OSRAM)
AU (1) AU2013221873B2 (OSRAM)
BR (1) BR112014019990A8 (OSRAM)
CA (1) CA2864420C (OSRAM)
CL (1) CL2014002096A1 (OSRAM)
CO (1) CO7061078A2 (OSRAM)
CY (1) CY1118899T1 (OSRAM)
DK (1) DK2814829T3 (OSRAM)
EA (1) EA027925B1 (OSRAM)
ES (1) ES2615268T3 (OSRAM)
HK (1) HK1204326A1 (OSRAM)
HR (1) HRP20170334T1 (OSRAM)
HU (1) HUE033704T2 (OSRAM)
IL (1) IL233965B (OSRAM)
LT (1) LT2814829T (OSRAM)
MX (1) MX350539B (OSRAM)
PE (1) PE20141791A1 (OSRAM)
PL (1) PL2814829T3 (OSRAM)
PT (1) PT2814829T (OSRAM)
RS (1) RS55763B1 (OSRAM)
SG (1) SG11201404667XA (OSRAM)
SI (1) SI2814829T1 (OSRAM)
SM (1) SMT201700137T1 (OSRAM)
TW (1) TW201336851A (OSRAM)
WO (1) WO2013122823A1 (OSRAM)
ZA (1) ZA201406723B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CA2921401A1 (en) * 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
ES2898273T3 (es) 2014-03-20 2022-03-04 Bristol Myers Squibb Co Moléculas con una estructura a base de fibronectina estabilizada
EP3789399A1 (en) 2014-11-21 2021-03-10 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
LT3221363T (lt) 2014-11-21 2020-08-10 Bristol-Myers Squibb Company Antikūnai prieš cd73 ir jų panaudojimas
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
WO2016112282A1 (en) * 2015-01-08 2016-07-14 The Scripps Research Institute Anticancer drug candidates
US10676773B2 (en) 2015-03-10 2020-06-09 Bristol-Myers Squibb Company Antibodies conjugatable by transglutaminase and conjugates made therefrom
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
WO2017053619A1 (en) 2015-09-23 2017-03-30 Bristrol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
WO2017112624A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
CN106267188B (zh) * 2016-08-15 2025-06-17 深圳大学 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR20240149979A (ko) 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
CN111683686A (zh) * 2017-12-06 2020-09-18 西纳福克斯股份有限公司 烯二炔缀合物
CN110183659B (zh) * 2018-02-21 2022-04-26 香港科技大学 含有杂环的聚合物、其制备方法及其应用
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
CN113453725A (zh) 2018-11-30 2021-09-28 百时美施贵宝公司 包含含有谷氨酰胺的轻链c末端延伸的抗体、其缀合物以及方法和用途
CN113544155A (zh) 2018-12-12 2021-10-22 百时美施贵宝公司 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
EP3972981A4 (en) * 2019-05-22 2023-05-24 Board of Regents, The University of Texas System Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
IL309249A (en) 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
US5162330A (en) * 1990-11-05 1992-11-10 Bristol-Myers Squibb Co. Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2002096910A1 (en) 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1471938A4 (en) 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
MXPA06000798A (es) 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US8170637B2 (en) * 2008-05-06 2012-05-01 Neurosky, Inc. Dry electrode device and method of assembly
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
BRPI0617549A2 (pt) 2005-09-26 2011-07-26 Medarex Inc anticorpo monoclonal humano isolado, anticorpo monoclonal humano isolado ou uma porÇço ligante ao antÍgeno do mesmo, composiÇço, imunoconjugado, molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-cd70, mÉtodo para tratar ou prevenir uma doenÇa, mÉtodo para tratar uma doenÇa autoimune em um indivÍduo, mÉtodo para tratar uma inflamaÇço em um indivÍduo, mÉtodo para tratar uma infecÇço viral em um indivÍduo, anticorpo ou porÇço ligante ao antÍgeno do mesmo e uso de um anticorpo ou de uma porÇço ligante ao antÍgeno do mesmo
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
WO2007038868A2 (en) * 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
ATE534629T1 (de) 2005-10-26 2011-12-15 Medarex Inc Verfahren und verbindungen zur herstellung von cc-1065-analoga
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
KR100869414B1 (ko) 2005-12-13 2008-11-21 야마하 가부시키가이샤 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기
ATE542888T1 (de) 2006-09-08 2012-02-15 Ambrx Inc Standortspezifische inkorporation nicht natürlicher aminosäuren in wirbeltierzellen
BRPI0717902A2 (pt) 2006-12-01 2013-10-29 Medarex Inc "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
HRP20150074T1 (hr) 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof

Also Published As

Publication number Publication date
CN104220441A (zh) 2014-12-17
US20130209494A1 (en) 2013-08-15
KR101660146B1 (ko) 2016-09-26
PT2814829T (pt) 2017-02-15
TW201336851A (zh) 2013-09-16
MX350539B (es) 2017-09-08
HRP20170334T1 (hr) 2017-04-21
CA2864420A1 (en) 2013-08-22
AU2013221873B2 (en) 2016-11-17
BR112014019990A2 (OSRAM) 2017-06-20
MX2014009234A (es) 2014-11-10
HK1204326A1 (en) 2015-11-13
JP2015508074A (ja) 2015-03-16
SI2814829T1 (sl) 2017-02-28
CA2864420C (en) 2016-11-15
LT2814829T (lt) 2017-02-27
JP6113194B2 (ja) 2017-04-12
SMT201700137T1 (it) 2017-05-08
US8709431B2 (en) 2014-04-29
ZA201406723B (en) 2016-05-25
EP2814829A1 (en) 2014-12-24
EA027925B1 (ru) 2017-09-29
PL2814829T3 (pl) 2017-06-30
CN104220441B (zh) 2017-03-29
BR112014019990A8 (pt) 2017-07-11
CL2014002096A1 (es) 2014-11-28
AU2013221873A1 (en) 2014-10-02
KR20140120374A (ko) 2014-10-13
WO2013122823A1 (en) 2013-08-22
EA201491447A1 (ru) 2014-11-28
EP2814829B1 (en) 2016-12-07
US9156850B2 (en) 2015-10-13
CY1118899T1 (el) 2018-01-10
CO7061078A2 (es) 2014-09-19
US20140193438A1 (en) 2014-07-10
AR089972A1 (es) 2014-10-01
DK2814829T3 (en) 2017-03-20
PE20141791A1 (es) 2014-11-19
HUE033704T2 (en) 2017-12-28
SG11201404667XA (en) 2014-09-26
RS55763B1 (sr) 2017-07-31
ES2615268T3 (es) 2017-06-06

Similar Documents

Publication Publication Date Title
IL233965B (en) History (2s, 5z, 9r 10s, 20r)-8,7,4,3-tetra-dehydro-18,13,9,2-tetra-hydro-18,13-dioxo-h1- 10,20,10 -(epoxy-methano)anthra[2,1-b]azacyclo-dodecine as anti-cancer drugs and their conjugates with antibodies and antigens
HUE045348T2 (hu) Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
IL238323A0 (en) Antibody/drug conjugates and methods of use
IL233757A0 (en) Anti '1m e-gi antibodies and methods of using them
PL3238709T3 (pl) Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
EP2927227A4 (en) ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
SI2796460T1 (sl) Pirolni šestčlenski derivat heteroarilnega obroča, postopek priprave zanj in medicinske uporabe le-tega
EP2670440A1 (en) Human antibodies and antibody-drug conjugates against cd74
PH12014501039A1 (en) Cytotoxic peptides and antibody drug conjugates thereof
SG10201500552PA (en) Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
ZA201404625B (en) Polycyclic derivatives, preparation method and medical uses thereof
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
EP2831059A4 (en) PROCESSES FOR PREPARING TUBULYSIN DERIVATIVES AND CONJUGATES THEREOF
ZA201407021B (en) Novel thienopyrimidine derivatives,processes for the preparation thereof and therapeutic uses thereof
PL2562172T3 (pl) Pochodne sfelaktonu, ich kompozycje farmaceutyczne, sposoby wytwarzania i zastosowania
IL229567A0 (en) Benzylidine-2h benzene [b] [4,1]thiazine-3(4h)-converted ones, their derivatives, and their medical uses
IL238223B (en) Nanoparticle mhc antigen complex, method for preparation and composition containing it
EP2683242A4 (en) EFFICIENT AMOUNT OF (3AR-) 1,3A, 8-TRIMETHYL-1,2,3,3A, 8,8A-HEXAHYDROPYRROLO- [2,3-B] INDOL-5-YL-PHENYL CARBAMATE AND PROCESS THEREFOR
IL239146A0 (en) Aminocyclobutane derivatives, methods for their preparation and their use as drugs
EP3003317A4 (en) Parthenolide derivatives, methods for their preparation and their use as anticancer agents
PT2849745T (pt) Composição farmacêutica compreendendo (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano[3,4,b]indol]-4-amina e ibuprofeno
ZA201206722B (en) Sealer elements,detonators containing the same, and methods of making
IL230655A0 (en) N-hetero-ring-substituted amide derivatives, compositions comprising the same and uses thereof
LT2849746T (lt) Farmacinė kompozicija, apimanti (1r,4r)-6`-fluor-n,n-dimetil-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano [3,4,b]indol]-4-aminą ir meloksikamą
EP3077400A4 (en) FURO[3,4-b]PYRAN COMPOUNDS AND PHARMACEUTICAL USES

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed